Candidate inhibitors of porcine complement

Molecular Immunology

Volumn 44, Issue 8, 2007, Pages 1827-1834

  Thorgersen, Ebbe B ^a   Ghebremariam, Yohannes T ^b   Thurman, Joshua M ^c   Fung, Michael ^d   Nielsen, Erik Waage ^e   Holers, V Michael ^c   Kotwal, Girish J ^b   Mollnes, Tom Eirik ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF COLORADO   (United States)

^d Tanox Biosystems Inc   (United States)

^e NORDLAND HOSPITAL   (Norway)

Author keywords

Anti factor B; Anti factor D; C1 inhibitor; Complement; Complement inhibitors; Escherichia coli; FUT 175; Porcine; Vaccinia virus complement control protein (VCP)

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE ANTIBODY; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; ENZYME ANTIBODY; FACTOR D ANTIBODY; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NAFAMSTAT MESILATE; RECOMBINANT PROTEIN; SERINE PROTEINASE INHIBITOR; VACCINIA VIRUS COMPLEMENT CONTOL PROTEIN; ZYMOSAN;

ARTICLE; COMPLEMENT INHIBITION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ESCHERICHIA COLI; NONHUMAN; PRIORITY JOURNAL; SWINE; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; COMPLEMENT ACTIVATION; DOSE RESPONSE; RODENT;

ANIMALIA; ESCHERICHIA COLI; RODENTIA; SUIDAE; SUS SCROFA; VACCINIA VIRUS;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT MEMBRANE ATTACK COMPLEX; DOSE-RESPONSE RELATIONSHIP, DRUG; RODENTIA; SWINE;

EID: 37849189360     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2006.10.004     Document Type: Article

References (52)

1. Al-Mohanna F., Parhar R., and Kotwal G.J. Vaccinia virus complement control protein is capable of protecting xenoendothelial cells from antibody binding and killing by human complement and cytotoxic cells. Transplantation 71 (2001) 796-801
2. Amsterdam E.A., Stahl G.L., Pan H.L., Rendig S.V., Fletcher M.P., and Longhurst J.C. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am. J. Physiol. 268 (1995) H448-H457
3. Anderson J.B., Smith S.A., van W.R., Chien S., and Kotwal G.J. Vaccinia virus complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding and complement pathway activation. Transpl. Immunol. 11 (2003) 129-135
4. Anderson J.B., Smith S.A., van W.R., Chien S., and Kotwal G.J. Vaccinia virus complement control protein ameliorates hyperacute xenorejection by inhibiting xenoantibody binding. Transplant. Proc. 34 (2002) 3277-3281
5. Arumugam T.V., Shiels I.A., Woodruff T.M., Granger D.N., and Taylor S.M. The role of the complement system in ischemia-reperfusion injury. Shock 21 (2004) 401-409
6. Brouwer N., Dolman K.M., van Z.R., Nieuwenhuys E., Hart M., Aarden L.A., Roos D., and Kuijpers T.W. Mannan-binding lectin (MBL)-mediated opsonization is enhanced by the alternative pathway amplification loop. Mol. Immunol. 43 (2006) 2051-2060
7. Caliezi C., Wuillemin W.A., Zeerleder S., Redondo M., Eisele B., and Hack C.E. C1-esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol. Rev. 52 (2000) 91-112
8. Fearon D.T., and Austen K.F. Activation of the alternative complement pathway due to resistance of zymosan-bound. Proc. Natl. Acad. Sci. U.S.A. 74 (1977) 1683-1687
9. Fujii S., and Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim. Biophys. Acta 661 (1981) 342-345
10. Fung M., Loubser P.G., Undar A., Mueller M., Sun C., Sun W.N., Vaughn W.K., and Fraser Jr. C.D. Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits. J. Thorac. Cardiovasc. Surg. 122 (2001) 113-122
11. Fust G., Medgyesi G.A., Rajnavolgyi E., Csecsi-Nagy M., Czikora K., and Gergely J. Possible mechanisms of the first step of the classical complement activation pathway: binding and activation of C1. Immunology 35 (1978) 873-884
12. Ghebremariam Y.T., Odunuga O.O., Janse K., and Kotwal G.J. Humanized recombinant vaccinia virus complement control protein (hrVCP) with three amino acid changes, H98Y, E102K, and E120K creating an additional putative heparin binding site, is 100-fold more active than rVCP in blocking both classical and alternative complement pathways. Ann. N. Y. Acad. Sci. 1056 (2005) 113-122
13. Goldfarb R.D., and Parrillo J.E. Complement. Crit. Care Med. 33 (2005) S482-S484
14. Harboe M., Ulvund G., Vien L., Fung M., and Mollnes T.E. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin. Exp. Immunol. 138 (2004) 439-446
15. Hicks R.R., Keeling K.L., Yang M.Y., Smith S.A., Simons A.M., and Kotwal G.J. Vaccinia virus complement control protein enhances functional recovery after traumatic brain injury. J. Neurotrauma 19 (2002) 705-714
16. Ikari N., Sakai Y., Hitomi Y., and Fujii S. New synthetic inhibitor to the alternative complement pathway. Immunology 49 (1983) 685-691
17. Imaizumi H., Kida M., Nishimaki H., Okuno J., Kataoka Y., Kida Y., Soma K., and Saigenji K. Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit. Pancreas 28 (2004) 369-373
18. Jha P., and Kotwal G.J. Vaccinia complement control protein: multi-functional protein and a potential wonder drug. J. Biosci. 28 (2003) 265-271
19. Jha P., Smith S.A., Justus D.E., and Kotwal G.J. Vaccinia virus complement control protein ameliorates collagen-induced arthritic mice. Ann. N. Y. Acad. Sci. 1056 (2005) 55-68
20. Jiang H., Wagner E., Zhang H., and Frank M.M. Complement 1 inhibitor is a regulator of the alternative complement pathway. J. Exp. Med. 194 (2001) 1609-1616
21. Kobayashi C., Matsunami K., Omori T., Nakatsu S., Nakahata K., Xu H., Fukuzawa M., Shirakura R., and Miyagawa S. Features of a newly cloned pig C1 esterase inhibitor1. J. Biochem. (Tokyo) 140 (2006) 421-427
22. Kotwal G.J., Isaacs S.N., McKenzie R., Frank M.M., and Moss B. Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science 250 (1990) 827-830
23. Kotwal G.J., and Moss B. Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature 335 (1988) 176-178
24. Linton S.M., and Morgan B.P. Complement activation and inhibition in experimental models of arthritis. Mol. Immunol. 36 (1999) 905-914
25. Miyata M., Shirakawa T., Acharya B., Terao S., and Gotoh A. Effects of nafamostat mesilate on ADP-induced platelet aggregation and disaggregation in hemodialysis patients. ASAIO J. 52 (2006) 272-275
26. Mohr M., Hopken U., Oppermann M., Mathes C., Goldmann K., Siever S., Gotze O., and Burchardi H. Effects of anti-C5a monoclonal antibodies on oxygen use in a porcine model of severe sepsis. Eur. J. Clin. Invest. 28 (1998) 227-234
27. Mollnes T.E., and Kirschfink M. Strategies of therapeutic complement inhibition. Mol. Immunol. 43 (2006) 107-121
28. Mollnes T.E., Lea T., Frøland S.S., and Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand. J. Immunol. 22 (1985) 197-202
29. Mollnes T.E., Redl H., Hogasen K., Bengtsson A., Garred P., Speilberg L., Lea T., Oppermann M., Gotze O., and Schlag G. Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin. Exp. Immunol. 91 (1993) 295-300
30. Mollnes T.E., Redl H., Hogasen K., Bengtsson A., Garred P., Speilberg L., Lea T., Oppermann M., Gotze O., and Schlag G. Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin. Exp. Immunol. 91 (1993) 295-300
31. Mollnes T.E., Song W.C., and Lambris J.D. Complement in inflammatory tissue damage and disease. Trends Immunol. 23 (2002) 61-64
32. Murthy K.H., Smith S.A., Ganesh V.K., Judge K.W., Mullin N., Barlow P.N., Ogata C.M., and Kotwal G.J. Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans. Cell 104 (2001) 301-311
33. Pfeifer P.H., Kawahara M.S., and Hugli T.E. Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. Clin. Chem. 45 (1999) 1190-1199
34. Pierre A.F., Xavier A.M., Liu M., Cassivi S.D., Lindsay T.F., Marsh H.C., Slutsky A.S., and Keshavjee S.H. Effect of complement inhibition with soluble complement receptor 1 on pig allotransplant lung function. Transplantation 66 (1998) 723-732
35. Pillay N.S., Kellaway L.A., and Kotwal G.J. Administration of vaccinia virus complement control protein shows significant cognitive improvement in a mild injury model. Ann. N. Y. Acad. Sci. 1056 (2005) 450-461
36. Reynolds D.N., Smith S.A., Zhang Y.P., Mengsheng Q., Lahiri D.K., Morassutti D.J., Shields C.B., and Kotwal G.J. Vaccinia virus complement control protein reduces inflammation and improves spinal cord integrity following spinal cord injury. Ann. N. Y. Acad. Sci. 1035 (2004) 165-178
37. Robbins R.A., Russ W.D., Rasmussen J.K., and Clayton M.M. Activation of the complement system in the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 135 (1987) 651-658
38. Scott M.J., Burch P.T., Jha P., Peyton J.C., Kotwal G.J., and Cheadle W.G. Vaccinia virus complement control protein increases early bacterial clearance during experimental peritonitis. Surg. Infect. (Larchmt.) 4 (2003) 317-326
39. Seelen M.A., Roos A., Wieslander J., Mollnes T.E., Sjoholm A.G., Wurzner R., Loos M., Tedesco F., Sim R.B., Garred P., Alexopoulos E., Turner M.W., and Daha M.R. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J. Immunol. Meth. 296 (2005) 187-198
40. Smith S.A., Krishnasamy G., Murthy K.H., Cooper A., Bromek K., Barlow P.N., and Kotwal G.J. Vaccinia virus complement control protein is monomeric, and retains structural and functional integrity after exposure to adverse conditions. Biochim. Biophys. Acta 1598 (2002) 55-64
41. Szebeni J., Fontana J.L., Wassef N.M., Mongan P.D., Morse D.S., Dobbins D.E., Stahl G.L., Bunger R., and Alving C.R. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 99 (1999) 2302-2309
42. Taube C., Thurman J.M., Takeda K., Joetham A., Miyahara N., Carroll M.C., Dakhama A., Giclas P.C., Holers V.M., and Gelfand E.W. Factor B of the alternative complement pathway regulates development of airway hyperresponsiveness and inflammation. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 8084-8089
43. Thorbjornsdottir P., Kolka R., Gunnarsson E., Bambir S.H., Thorgeirsson G., Kotwal G.J., and Arason G.J. Vaccinia virus complement control protein diminishes formation of atherosclerotic lesions: complement is centrally involved in atherosclerotic disease. Ann. N. Y. Acad. Sci. 1056 (2005) 1-15
44. Thurman J.M., Kraus D.M., Girardi G., Hourcade D., Kang H.J., Royer P.A., Mitchell L.M., Giclas P.C., Salmon J., Gilkeson G., and Holers V.M. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol. Immunol. 42 (2005) 87-97
45. Thurman J.M., Royer P.A., Ljubanovic D., Dursun B., Lenderink A.M., Edelstein C.L., and Holers V.M. Treatment with an inhibitory monoclonal antibody to mouse factor B protects mice from induction of apoptosis and renal ischemia/reperfusion injury. J. Am. Soc. Nephrol. 17 (2006) 707-715
46. Tofukuji M., Stahl G.L., Agah A., Metais C., Simons M., and Sellke F.W. Anti-C5a monoclonal antibody reduces cardiopulmonary bypass and cardioplegia-induced coronary endothelial dysfunction. J. Thorac. Cardiovasc. Surg. 116 (1998) 1060-1068
47. Volanakis J.E., and Narayana S.V. Complement factor D, a novel serine protease. Protein Sci. 5 (1996) 553-564
48. Ward P.A. The dark side of C5a in sepsis. Nat. Rev. Immunol. 4 (2004) 133-142
49. Welch T.R. Complement in glomerulonephritis. Nat. Genet. 31 (2002) 333-334
50. Wouters D., Voskuyl A.E., Molenaar E.T., Dijkmans B.A., and Hack C.E. Evaluation of classical complement pathway activation in rheumatoid arthritis: measurement of C1q-C4 complexes as novel activation products. Arthritis Rheum. 54 (2006) 1143-1150
51. Yao Y.M., Redl H., Bahrami S., and Schlag G. The inflammatory basis of trauma/shock-associated multiple organ failure. Inflamm. Res. 47 (1998) 201-210
52. Zarkadis I.K., Mastellos D., and Lambris J.D. Phylogenetic aspects of the complement system. Dev. Comp. Immunol. 25 (2001) 745-762